Loading…
← CockpitCompetitor Analysis › BLLN BillionToOne, Inc. Class AOpen in the cockpit ↗

BillionToOne, Inc. Class ABLLNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Genetic testing company known for its UNITY noninvasive prenatal test and an expanding oncology molecular residual disease testing menu.

Momentum weak 37
Mkt cap
$4.37B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$77.0M
20-day average traded
Fwd P/E
115.3×
forward earnings
ROIC−WACC
+17.7 pp
WACC 6.5%
Hurdle
-49 pp
Req g minus delivered
Next earnings
112 days
10 Mar 2027
Close · USD$91.54
1D-6.1%
1W-17.0%
1M-11.6%
3M-22.4%
6M+7.1%
YTD+11.8%
1Yn/a
ATR %7.9%
Beta1.48
52w lowhigh39.1% off high

What BillionToOne does

Genetic testing company known for its UNITY noninvasive prenatal test and an expanding oncology molecular residual disease testing menu.

Runs the tests in its own labs and bills insurers or patients for each one, so revenue depends on test volume and how much payers reimburse. Obstetricians and maternal-fetal specialists order the prenatal tests, which carry sales; oncologists order the newer cancer-monitoring tests.

Products and services

  • UNITY noninvasive prenatal screening
  • Oncology molecular residual disease testing (Northstar)

Customers

  • OB/GYNs and maternal-fetal medicine specialists
  • Oncologists
  • Expectant parents

Where it sits in the supply chain

  • Healthcare
  • Diagnostics/genetic testing
  • Prenatal and oncology molecular…

What could go right

  • Prenatal test volume/reimbursement growth
  • Oncology testing market entry

What could go wrong

  • Reimbursement/payer coverage risk
  • Competitive intensity from Natera

Moat: narrow (IP / patents, data). Proprietary quantitative counting (QCT) sequencing technology differentiates its prenatal test accuracy claims.

Headquarters: Menlo Park, California, USA · Founded: 2016 · Employees: 713

Named competitors

BillionToOne at a glance

Size BillionToOne (BLLN) is a United States Health Care company (Medical/Nursing Services) with a market value of $4.37B, the 1274th largest of 3,085 United States companies the cockpit tracks. Shares closed at $91.54 on 18 Nov 2026.

Performance Over six months the shares gained 7.1%, against +28.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 71.9% over the last twelve months (peer median +11.3%); the operating margin is 10.2% (peer median 8.9%).

Valuation It trades at 115.3× forward earnings against a peer median of 33.0× (most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +72%, so the hurdle is -49 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 17.7 points above its cost of capital (6.5% WACC).

Backlog Backlog (remaining performance obligations) was $4.70M at 30 Sep 2025. Backlog detail →

Short interest Short interest is 6.9% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 130BLLN 103
Six months, rebased to 100: BillionToOne against the median of its 20 peers (local-currency closes).

BillionToOne financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$437M$305M$153M$71.7M
Revenue growth—+100%+113%—
Gross profit$312M$208M$80.9M$17.3M
EBITDA$57.6M$27.9M-$35.5M-$63.0M
Net income$47.8M$2.92M-$41.6M-$82.7M
Free cash flow$33.9M$15.7M-$46.8M-$59.8M
Capital expenditure$14.0M$8.92M$5.40M$6.17M
Total debt$140M$109M$109M$146M

Quarterly statements and history in the cockpit →

BillionToOne competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-25%0%+25%OPCHHIMSMCOV-BLFSTCONLALPATHLABACHCSHL002044MDAVAHALIF-BAZTANEODVAAGARWALEYE603882BLLN6-month return →1-month return →
Up and to the right = strong over both horizons. BillionToOne is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×OPCHMCOV-BLFSTCONLALPATHLABACHCRDNTSHL002044MDAVAHALIF-BAZTANEOAGARWALEYE603882BLLNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BillionToOne is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%3774OPCHMCOV-BLFSTCONLALPATHLABRDNTSHLMDALIF-BAZTAAGARWALEYE603882BLLNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BillionToOne is the large dot.

BillionToOne competitors and peer comparison

Head to head with its named competitors (BLLN vs NTRA vs LH vs ILMN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BillionToOne BLLN$4.37B+7%+72%10%115.3×22.8%
Natera NTRA$42.0B+41%+37%-9%n/an/a
Labcorp LH$30.1B+44%+6%11%19.3×14.5%
Illumina ILMN$31.8B+48%+6%21%35.2×27.2%

How BillionToOne compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BillionToOne against its 20 peers (data as of 18 Nov 2026)
MeasureBLLNPeer medianRank in peer set
1-month return-11.6%+2.8%4th lowest of 21
6-month return+7.1%+28.9%6th lowest of 20
Distance from 52-week high-39.1%-10.5%3rd lowest of 21
Revenue growth (TTM)+71.9%+11.3%highest of 21
Operating margin10.2%8.9%9th highest of 21
Forward P/E115.3×33.0×most expensive of 19
Growth the price implies (Req g, 7 yrs)22.8%9.1%7th most demanding of 18
Growth delivered (Del g)+71.9%+11.8%highest of 18
Hurdle (Req g minus delivered)-49.1 pp+2.9 ppleast demanding of 18
ROIC minus cost of capital+17.7 pp+0.0 pp3rd highest of 21
EV / EBITDA68.6×13.9×most expensive of 16
Net debt / EBITDA-7.3×2.8×least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BillionToOne BLLNUnited States$4.37B+7%+72%10%115.3×22.8%+71.9%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
Option Care Health OPCHUnited States$4.75B+43%+4%6%15.7×2.0%+13.2%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%n/an/an/a
Medicover MCOV-B.STSweden$3.87B+21%+3%7%36.1×19.6%+20.2%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%51.8×33.4%+30.4%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%22.3×3.6%+7.9%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%50.5×32.3%+11.8%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%18.6×n/an/a
RadNet RDNTUnited States$5.66B+32%+21%5%93.2×38.8%+13.7%
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%17.4×9.1%+3.5%
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%49.6×4.2%+5.7%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%12.4×-4.4%+2.0%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%12.2×7.7%+10.2%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
DaVita DVAUnited States$10.2B-18%+6%15%10.1×-2.5%+3.4%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%

BillionToOne backlog

BillionToOne reported $4.70M of remaining performance obligations at 30 Sep 2025.

Questions

Who are BillionToOne's main competitors?
Named competitors: Natera (NTRA), Labcorp (prenatal testing) (LH), Illumina (ILMN). The cockpit's measured peer set (industry) also includes Fameglow (3774.HK), Option Care Health (OPCH), Hims & Hers Health (HIMS), Medicover (MCOV-B.ST), Lifestance Health (LFST), Concentra Group Holdings Parent (CON).
Is BillionToOne expensive compared with its peers?
On forward p/e it trades at 115.3× against a peer median of 33.0×, most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +72%, so the hurdle is -49 pp: the price already allows for a slowdown.
How has BillionToOne stock performed?
Over six months to 18 Nov 2026 the shares returned +7.1% against +28.9% for the median peer.
What is BillionToOne's backlog?
BillionToOne's remaining performance obligations (contracted revenue not yet recognised) were $4.70M at 30 Sep 2025.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.